News

HDL-C level >80 mg/dL was associated with higher risk of all-cause and cardiovascular death in patients with CAD, compared with those with normal HDL-C levels.

Montefiore's Carol A. Bernstein, MD, discusses the role of psychiatry specialists in discerning their colleagues' need for mental health care or resolutions to burnout.

The majority of treatment emergent adverse events were mild to moderate in severity.

The study authors suggest a thinner macular RNFL may predict a decline in cognitive performance.

Despite being rare, little is known regarding the pathophysiology of DLLR following COVID-19 vaccination.

Dr. Brown and Mr. Zavodnick speak on the first and only FDA-approved steroid-free topical medication in its class approved for psoriasis, and the data that bolstered this approval.

Severe or inflammatory acne can result in prominent scarring in affected patients, which highlights the importance of grading acne in diagnosis of the skin condition.

The investigators found pharmacotherapy for AUD was associated with a lower incidence of hepatic decompensation in patients with cirrhosis.

Efanescotocog alfa is the first factor VIII therapy to be granted Breakthrough Therapy designation by the FDA.

Investigators observed that patients with quantifiable levels of brodalumab following 12 weeks of therapy experienced significantly higher PASI reductions that those without.

Since the delivery of these medications were disrupted during the pandemic, members of racial and ethnic minority groups experienced an increased risk of opioid overdose, compared with White individuals.

The NDA submission is based on results from the Phase 3 DERBY and OAKS studies and the Phase 2 FILLY study.

Fidaxomicin had a 13.5% higher rate of 4-week sustained response compared to vancomycin and 13.2% higher rate for 8-week sustained response.

Patients with ≥1 CDI-related admissions versus no CDI admissions experienced higher rates of 6-month readmission and annual cost across all hospitalizations.

AXS-05 also showed superiority to placebo in safety.

A greater prevalence of hidradenitis suppurativa, psoriasis, folliculitis, and hirsutism in pediatric patients with obesity compared to the general pediatric population.

SER-109 engraftment was durable through week 24 and significantly higher than placebo at all time points for all comparisons.

Most adverse events reported were mild or moderate and found in a similar percentage of patients regardless of treatment cohort.

New data suggests there is no connection between ustekinumab and the risk of malignancies.

While the long-term efficacy and safety of the biologic has been investigated in, few studies have been based on real life experience.

There are several companies preparing new treatments for recurrent C difficile infections.

Dupilumab is the first and only biologic to show positive Phase 3 results in patients with prurigo nodularis.

There are several potential treatments on the horizon for C difficile infections.

The meta-analysis included more than 11,000 patients with between 8 and 9 years of mean follow-up periods.

Screening and early-life interventions for these patients may prevent cardiometabolic outcomes, according to investigators.

Primary care provider Dr. Gerald Smetana shares key information and resources to give PCPs all they need know about prescribing outpatient therapies for COVID-19.

The public perception of marijuana has shifted significantly, and Dr. Timothy Fong addresses how to keep up with progressive research and what risk factors still need to be better understood.

EoE expert Dr. Marc Rothenberg says it's a relief to know that the FDA has finally approved a drug for EoE.